LAVAL, QC, Jan. 21, 2021 /PRNewswire/ -- Bausch + Lomb,
a leading global eye health business of Bausch Health Companies
Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that
LUMIFY® (brimonidine tartrate ophthalmic solution
0.025%) redness reliever eye drops have received approval from the
Ministry of Food and Drug Safety (MFDS) in South Korea.
"The approval of LUMIFY in South
Korea marks another step in our global rollout of these
innovative redness reliever eye drops," said Thomas J. Appio, president, Bausch +
Lomb/International. "LUMIFY will be a welcome addition to our
portfolio of eye health products in South
Korea, and we expect LUMIFY will be available to consumers
in South Korea in the second half
of 2021."
Since its initial U.S. approval in 2017, LUMIFY has achieved the
No. 1 dollar share among redness relievers (at 40% share in the
latest 52 weeks)1, became the No. 1 eye doctor
recommended brand within the first few months of
launch,2 and brought in more than a million first-time
users into the eye redness reliever category3 in
the United States.
Additional regulatory submissions for LUMIFY are underway in
multiple countries.
About LUMIFY Redness Reliever Eye Drops
In
the United States and Korea,
LUMIFY is the first and only over-the-counter eye drop developed
with low dose brimonidine tartrate 0.025% for the relief of redness
of the eye due to minor eye irritations. Unlike other redness
relievers, LUMIFY selectively targets redness, with a reduced risk
of certain side effects, including rebound redness and loss of
efficacy over time, when used as directed. For more information on
LUMIFY, U.S. residents can visit www.lumifydrops.com.
About Bausch + Lomb
Bausch + Lomb, a leading global
eye health business of Bausch Health Companies Inc., is solely
focused on helping people see better to live better. Its core
businesses include over-the-counter products, dietary supplements,
eye care products, ophthalmic pharmaceuticals, contact lenses, lens
care products, ophthalmic surgical devices and instruments. Bausch
+ Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in the industry, which is
available in approximately 100 countries. For more information,
visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "believes,"
"estimates," "potential," "target," or "continue" and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in the Bausch Health's most
recent annual report on Form 10-K and detailed from time to time in
Bausch Health's other filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include,
but are not limited to, risks and uncertainties caused by or
relating to the evolving COVID-19 pandemic, and the fear of that
pandemic and its potential effects, the severity, duration and
future impact of which are highly uncertain and cannot be
predicted, and which may have a material adverse impact on Bausch
Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
- Consumer Data Science: Total US Omnichannel Data Ending
12-27-20.
- Consumer Data Science: IQVIA ProVoice Data Ending Q4 2020.
- Consumer Data Science: IRI, Total US All Outlet Panel Data
Ending 12-27-20.
LUMIFY is a trademark of Bausch & Lomb Incorporated or
its affiliates. Any other product/brand names are trademarks of the
respective owners. © 2021 Bausch & Lomb Incorporated or its
affiliates.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/south-koreas-mfds-approves-lumify-eye-drops-301212137.html
SOURCE Bausch Health Companies Inc.